RE: Rare as rocking horse ??6 Mar 2023 14:42
Everhopeful,
can you take us through an example scenario where another product comes along and makes FF redundant in a moment?
Would it be for gut health, hypertension, blood lipids, platelet aggregation, DVT, ruddy skin, reproductive health, reduction of exercise induced inflammation?
What would the existing customers do with their products, like Zaax, SOP Subarashi and VidaMaxx, would they just stop producing them?
Would By-health just stop with their submission to SAMR and not bother.
Would DSM not bother with marketing FF for gut-health?
Would Square Pharma cancel their ongoing trial?
Would those trying to get regulatory approval in Mexico, India and other countries just scrap their work to date?
Would like your insight.